



Making the invisible enemy visible  
 
Structural biology plays a crucial role in the fight against COVID-19, permitting us to ‘see’ and 
understand the SARS-CoV-2 virus. However, the macromolecular structures of SARS-CoV-2 proteins that 
were solved at great speed and urgency can contain errors that may hinder drug design. The Coronavirus 
Structural Task Force has been working behind the scenes to evaluate and improve these structures, 
making the results freely available at insidecorona.net.  
 
When the COVID-19 pandemic hit in early 2020, the structural biology community quickly swung into action to 
determine the atomic structures of the 28 viral proteins encoded by SARS-CoV-21. 1392 structures covering 18 
SARS-CoV-1 and SARS-CoV-2 (which comprise the subgenus sarbecovirus) proteins have been released over just 12 
months and are freely and publicly available in the World Wide Protein Data Bank (wwPDB), which celebrates its 50th 
anniversary this month. These models serve as the basis for structure-based drug design and vaccine development. 
They are also essential for understanding how the virus hijacks human cells and causes disease. However, errors 
occur in even the most carefully determined structures and may be still more common in structures solved quickly 
and under immense pressure. Yet, even small errors can have severe consequences for structure-based drug 
discovery, structural bioinformatics, and computational chemistry, because they can be misinterpreted as 
biologically and pharmaceutically relevant. 
While the wwPDB is an invaluable tool as structural biology’s archive of record, it is also near-static. Released 
structures can only be updated by the original depositors, but there is often little motivation to make corrections 
once associated papers are published. 99% of PDB structure downloads are not by experimental structural biologists 
per se, but by scientists who use the structural data2 and who might lack the training to identify and/or correct 
erroneous sites in the molecular model.  
In this global crisis, it is vital to ensure that the available structural data are the best they can be by pushing our 
methods to the limit. The Coronavirus Structural Task Force, a diverse international team of structural biologists 
involved in methods development, responded to this challenge by rapidly categorizing, evaluating, and reviewing all 
SARS-CoV-1 and SARS-CoV-2 experimental structures. We do a weekly automatic post-analysis as well as a manual 
re-processing and re-modelling of representative structures from each of the 18 structurally characterized 
sarbecovirus proteins. Every Wednesday, when new PDB structures are released, our automatic pipeline identifies 
new coronavirus structures and assesses the quality of models and experimental data. This assessment, along with 
the original structures, is immediately made available in our online repository (insidecorona.net). There, we also 
supply a summary, an SQL database of key statistics and quality indicators, and individual results. After our validation 
effort began we were approached by researchers involved in in-silico drug screening  from Folding@Home3, 
OpenPandemics4, and the EU Joint European Disruptive Initiative (JEDI). These groups aim to simulate the 
conformational flexibility and interaction of coronavirus proteins with each other and host cell proteins and to 
design small-molecule inhibitors against key SARS-CoV-2 targets via high-throughput computational modelling, a task 
that is exquisitely sensitive to the quality of the input model.  
In addition to structure evaluation and improvement, insidecorona.net supplies literature reviews centered on the 
structural aspects of the viral infection cycle, host interaction partners, illustrations, and advice on selecting the best 
starting models for in silico projects. Furthermore, we have added SARS-CoV-2 proteins to Proteopedia5 and 
molssi.org, as well as a 3D-Bionotes6 deep-link into our database. Finally, we have tried to make SARS-CoV-2-related 
research accessible to the general public with blog posts aimed at non-scientists. We also live streamed data 
processing on Twitch and provided an accurate 3D printed model of SARS-CoV-2 based on deposited structures 




All macromolecular structures from SARS-CoV-1 and SARS-CoV-2 in the wwPDB are downloaded into our repository 
and assessed automatically within 24 hours of release. We combine new validation tools with previously developed 
methods, many of which were adapted for our purposes. 
Crystallographic data and structure solutions 
73% of reported sarbecovirus structures are derived by X-ray crystallography. These datasets are evaluated for 
pathologies including twinning, multiple lattice diffraction, ice crystal contamination, incompleteness, and radiation 
damage using phenix.xtriage7 and AUSPEX8. Although these issues cannot be resolved after data collection, taking 
them into account during data processing and structure solution can yield better models. It can be difficult to 
identify these problems using deposited structure factors (the end result of processing raw diffraction data), since 
information is lost in the process. Raw data allow a more complete analysis of the experiment and re-processing - 
but can be difficult to obtain, as they are not deposited in the wwPDB or required for publication. We therefore 
invite authors to send us their raw experimental data and offer to deposit them in public repositories, such as 
SBGrid9 or proteindiffraction.org10. All data sets we have analyzed to date have an acceptable signal-to-noise ratio; 
we evaluated other statistical quality indicators, examples of which are summarized in Table 1.  
A general indication of how well the atomic model fits the measurement data is given by the R values: While only 
two structures in the our present alarmingly high Rfree values above 35%, this does not necessarily mean an absence 
of modelling problems. Large Rfree drops indicated major issues with PDB entries, especially for older SARS-CoV-1 
structures. PDB-REDO11 re-refinements generally improved Rfree. Nevertheless, the resulting models should not be 
viewed as “more correct” purely on the basis of a lower R value, particularly at lower resolution where the 
relationship between R values and model quality degrades12. Critical manual inspection of the model remains 
necessary.  
Structures from single-particle Cryo-EM 
Cryo-EM structures make up 24% of reported SARS-CoV-1 and SARS-CoV-2 structures. Raw data are not available 
from the wwPDB, but deposition into EMPIAR13 is increasingly common. The reconstructed 3D map deposited in the 
EMDB14 allows calculation of the fit between model and map by Fourier Shell Correlation (FSC) to assess agreement 
between features at different resolutions. FSCs, real-space Cross-Correlation Coefficient (CCC), Mutual Information 
(MI) and Segment Manders’ Overlap Coefficient (SMOC)15 were calculated with the CCP-EM16 model validation task 
(see Table 1). While MI and CCC are single value scores that indicate how well model and map agree overall, the 
SMOC score evaluates the fit of each modelled residue individually and can highlight specific regions where model 
and map disagree. We use Haruspex17, a neural network trained to recognize secondary structure elements and 
RNA/DNA in cryo-EM maps, as visual guidance for manual structure evaluation. 
 
Evaluation of the structural models based on prior knowledge 
MolProbity18 is used to evaluate the model quality, check covalent geometry and conformational parameters of 
protein and RNA, and steric clashes. Some of these traditional quality indicators are used as additional restraints 
during refinement, which reduces their usefulness as quality metrics. The newer MolProbity CaBLAM score6 is 
designed to find local errors and particularly useful at 3-4 Å resolution. Current refinement packages do not 
specifically aim at improving this score, arguably making it a more reliable quality indicator. In addition, checking the 
amino acid sequence of each model against the one specified in the deposited PDB file highlighted mismatches in 23 
cases. 
During the COVID19 crisis the MolProbity webservice has been pushed to its limit as drug developers screen the 
same SARS-CoV-2 structures many times. We developed a custom MolProbity pipeline which makes the validation 




Although the structural biology community has achieved a high level of automation in data collection, data 
processing and structure solution in recent years, the process of structure determination still requires interpretation 
by researchers. This especially applies to low-quality maps with poor fit between experimental data and structural 
models. Visual residue-by-residue inspection by an experienced structural biologist remains the best way to judge 
quality. We therefore select representative structures of each SARS-CoV-2 protein, as well as those of particular 
interest for drug development for manual evaluation. Certain problems are surprisingly common, such as peptide 
bond flips (Fig. 1C, 1D), rotamer errors, occupancy problems (Fig. 1E) and misidentification of small molecules or 
ions, e.g.  water as magnesium and chloride as zinc. Of note, zinc plays an important role in many SARS-CoV-2 
proteins. We found many zinc coordination sites to be mismodelled, with the zinc ion missing or pushed out of 
density and/or erroneous disulphide bonds between the coordinating cysteine residues (Fig. 1A, 1B, 1H). In addition, 
many coronavirus proteins are glycosylated at surface asparagine residues, but glycan sugars were often flipped 
from their correct orientation around the N-glycosidic bond (Fig. 1F, 1G). This can be avoided by using tools such as 
Privateer19 and the automated carbohydrate building tool in Coot20. It is important to note that deviation from 
expected behavior is not always an error and can also be a functionally relevant feature, e.g. the strained geometries 
often found at catalytic sites. However, such deviations must be strongly supported by the experimental data.  
Of the structures we checked manually, we were able to substantially improve 31 in terms of model quality, data 
quality, or both. Here we give two examples to illustrate the importance of careful inspection of experimental data 
and resulting models. 
Papain-like protease 
Nsp3 (SARS-CoV-2 Non-structural-protein 3) contains a papain-like protease domain that is essential for infection 
because it cleaves the viral polypeptide. The first SARS-CoV-2 structure (PDB 6W9C) was released 1st April 2020, only 
three months after the viral genome (GenBank: MN908947.2) was reported21, and it was immediately used in drug 
design efforts. The overall completeness of the measured data, however, was only 57%. Examination of the raw 
data, available from proteindiffraction.org10, revealed strong radiation damage, exacerbated by a poor data 
collection strategy. This could not be deduced from the PDB deposition, underlining the importance of the 
availability of raw data.  
The crystal has 3-fold non-crystallographic symmetry with each papain-like protease domain monomer containing a 
functionally important Zn2+ ion bound by four cysteines with similar Cß-Sγ-Zn angles and Zn- Sγ bond lengths. Because 
of radiation damage, these sites have poor density. One site has been modelled as a disulphide bond and two free 
cysteines (Fig. 1H) while the other two coordinated zinc with strongly varying Cß- Sγ-Zn angles and Zn-S bond lengths. 
We reprocessed the images using XDS22, a software for the processing of single-crystal X-ray diffraction images. The 
Staraniso server (http://staraniso.globalphasing.org) was used to determine and apply an anisotropic limit for the 
diffraction data. This careful manual intervention improved overall data quality and resolution from 2.7 to 2.6 Å, but 
the revised overall ellipsoidal completeness was only 44.5%. Adding zincs to all sites, restraining the bond lengths 
and angles to the expected values, using NCS (non-crystallographic symmetry) restraints and an overall higher 
weighting of ideal geometry, together with remodeling of side chains and water molecules improved the electron 
density maps and lowered the R values by 4%. This exemplifies the interconnection between data collection, data 
processing and model building: even if the data collection strategy is not ideal, taking the resulting problems into 
account during data processing and refinement can drastically improve the final model.  
 
A structure of the C111S mutant of Papain-like protease domain (PDB 6WRH) was released a month later. In this 
structure, the zinc sites were clearly resolved in all subunits. In the meantime, however, PDB 6W9C had been widely 
used in in silico drug design. 20% of the over 140 research teams in the JEDI COVID19 GrandChallenge, a competition 
to find potential drugs against COVID-19 in silico, have used this model. The availability of a better structure a month 
earlier would have increased their chances of success and saved computing and person hours. 
 
 
RNA polymerase complex 
SARS-CoV-2 replicates its single-stranded RNA genome using a macromolecular complex of RNA-dependent RNA 
polymerase (Nsp12; RdRp), Nsp7 and Nsp8 (SARS-CoV-2 Non-structural-proteins 7 and 8, respectively). Earlier Cryo-
EM structures of the SARS-CoV-1 homologs (PDB 6NUR, PDB 6NUS) include a disordered unmodeled loop followed 
by a visible but short and irregular helix and a flexible C-terminus. Density for this helix was poorly resolved, but the 
model had valid geometry. Our analysis of one of the first structures of the equivalent SARS-CoV-2 complex (PDB 
7BTF) revealed that the sequence in this C-terminal region (part of the RNA binding groove) was misaligned by nine 
residues (Fig. 2). This error was present in all related SARS-CoV-1 and SARS-CoV-2 structures, likely because new 
structure determination typically starts from an earlier model if one is available.  
A structure of the RdRp complex bound to the nucleotide analog remdesivir (PDB 7BV223) was released soon after 
and provided the basis for rational design of related drug candidates24. This structure also featured the 9-residue 
sequence misalignment.  We rebuilt the structure using ISOLDE, CaBLAM, and visual inspection, correcting some 
flipped or cis-vs-trans peptides (see Fig 1C, 1D) and three RNA conformers near remdesivir, including a backward 
adenosine base, and were able to add several residues and waters with good density and geometry. Remdesivir is 
covalently attached to the RNA, but it is only present in an estimated ≤ 50% of the measured molecules12. This 
means the active site is a mixture of at least two different states, so unsurprisingly the modeled Mg2+ ions and 
pyrophosphate are poorly supported by the experimental density and local contacts. This is of concern for 
subsequent in-silico docking and drug design, which often take all atoms in the deposited structure as a fixed 
framework to build into. The remodeled structures of the complex might offer a more solid basis for drug design 
even if the half-occupancy active site was not widely discussed12. It is notable that despite the very large register 
error and various smaller issues, by traditional “summary” metrics the model appeared extremely good, with no 
Ramachandran nor rotamer outliers and a clash score of 2, highlighting that direct visual inspection must remain a 
key step in any modelling process. 
Although the problems discussed above were present in the originally deposited structures, nearly all are now 
corrected. This was achieved by making corrected models available on our website and contacting the original 
authors of these structures with detailed descriptions, allowing them to deposit revised versions to the wwPDB at 
their discretion.  
In conclusion 
In the last 40 years, structural biology has achieved a high level of automation, and methods have advanced greatly. 
It is now feasible to solve a new structure from start to finish in a matter of weeks with little specialist knowledge. 
This is exemplified by the rapid solution of SARS-CoV-2 structures during the pandemic, which is a remarkable 
achievement. These structures have enabled rapid progress in the development of therapeutics and vaccines. 
However, errors at all stages of structure determination are not only common, but often remain undetected. 
Unfortunately, no individual researcher can be fully conversant with all the details of structure determination, 
chemical properties of interacting groups, catalytic mechanisms, and the viral infection cycle. While any molecular 
model could benefit from examination by multiple experts, it is particularly important to rapidly carry out such 
inspection of Coronavirus-related structures.  
Structural models are an interpretation of the measured data, and deposited structures could be seen as the first 
round of interpretation which may provide considerable biological insight but may leave room for improvement. The 
availability of raw data would allow more complete assessment of the structure solution. It would also offer the 
opportunity to reanalyze the data and to propose updates to the original authors or to deposit derivative models in 
the wwPDB. We believe that, as a community, we need to change how we see, address, and document errors in 
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Fig. 1 Potential for improvement. All pictures except I are screenshots from Coot 0.9.9-pre-release. Residual density and reconstructions maps in 
blue-gray; difference electron density in red and green. A. SARS coronavirus Nsp14-Nsp10 (PDB 5C8T) histidine zinc coordination site (B603) with 
residual density contour level 0.445, rmsd 0.150. B. Histidine from A has been swapped in ISOLDE, leading to tetrahedral coordination of Zn2+, 
followed by PDB-REDO refinement with manually added links. C. Proline A505 is modelled as trans in RdRp complex (PDB 7BV2, left) but density 
indicates a cis main chain conformation (D). The deposited PDB entry was updated after we contacted the original authors. E. High difference 
electron density at residue A165 in SARS-CoV-2 main protease (PDB 5RFA) due to only 0.44 occupancy instead of 1.00 near potential inhibitor 
(left). Residual map contour level 0.54, rmsd 0.319, difference density at contour level 0.35, rmsd 0.114. F. SARS-CoV-2 spike receptor binding 
domain complexed with human ACE2 (PDB 6VW1): this N-linked glycan is flipped approximately 180° around the N-glycosidic bond. After we 
contacted the original authors, this entry was revised - see G. Correction improves the density fit of the sugar chain. Residual map at contour level 
0.311 rmsd 0.265. H. Disulphide bond A226-A189 in papain-like protease (PDB 6W9C) with electron density at contour level 0.214 rmsd 0.136. 
While the density map does not indicate a zinc, it is a zinc finger domain; the other NCS copies have a zinc coordinated here and the other two 
cysteines are uncoordinated. I. AUSPEX8 plot of SARS-CoV main protease (PDB 2HOB); ice rings are reflected by a bias in the intensity distribution 
(red). J. Ramachandran plot or torsion angles in the peptide bond for SARS-CoV Nsp10/Nsp14 dynamic complex (PDB 5NFY); usually, there should 





Registry shift in C-terminus of RNA Polymerase. A. Overview with missing loop shown as dashed line (PDB 7BV2); map at 2.4σ. 
Right side: Details of C-terminal helix at 5σ. B. Lower resolution map and model PDB 6NUS. Judging the side chain fit is difficult. C. 
Higher resolution map and model PDB 7BV2 as deposited; the side chain fit is suboptimal due to the register error. D. Amended 






Key indicators in evaluation Number of depositions (% of total) 
Crystallography (999 depositions) 
Completeness < 80% 
Rfree > 35% 
Potential twinning 







Single-particle Cryo-EM (360 depositions) 
Average model-map FSC < 0.4 
MI score < 0.4 




Other indicators (1392 depositions) 
CaBLAM outlier conformations > 2.0% 310 (22%) 
CaBLAM severe Cα outliers > 1.0% 106 (7.6%) 
Sequence mismatch 23 (1.7%) 
 
Table 1. Examples of quality indicators pointing to potential problems in PDB entries, calculated in our automatic evaluation 
pipeline. Potential twinning as identified by L-Test7, ice diffraction and incorrect mask identified by visual inspection of AUSPEX 
plots8. The chosen cutoffs for FSC and MI score16 indicate poor overall agreement between map and model. The SMOC15 score > 






1. Baker, E. N. Visualizing an unseen enemy; mobilizing structural biology to counter COVID-19. Acta Cryst D 76, 
311–312 (2020). 
2. Burley, S. K. et al. RCSB Protein Data Bank: Sustaining a living digital data resource that enables breakthroughs in 
scientific research and biomedical education. Protein Science : A Publication of the Protein Society 27, 316 (2018). 
3. Zimmerman, M. I. et al. Citizen Scientists Create an Exascale Computer to Combat COVID-19. bioRxiv 
2020.06.27.175430 (2020) doi:10.1101/2020.06.27.175430. 
4. OpenPandemics - COVID-19 | Research | World Community Grid. 
https://www.worldcommunitygrid.org/research/opn1/overview.do. 
5. Proteopedia: A status report on the collaborative, 3D web-encyclopedia of proteins and other biomolecules. 
Journal of Structural Biology 175, 244–252 (2011). 
6. Prisant, M. G., Williams, C. J., Chen, V. B., Richardson, J. S. & Richardson, D. C. New tools in MolProbity validation: 
CaBLAM for CryoEM backbone, UnDowser to rethink “waters,” and NGL Viewer to recapture online 3D graphics. 
Protein Science 29, 315–329 (2020). 
7. Zwart, P. H., Grosse-Kunstleve, R. W. & Adams, P. D. Xtriage and Fest: automatic assessment of X-ray data and 
substructure structure factor estimation. 9. 
8. Thorn, A. et al. AUSPEX: a graphical tool for X-ray diffraction data analysis. Acta Cryst D 73, 729–737 (2017). 
9. Morin, A. et al. Cutting edge: Collaboration gets the most out of software. eLife 2, (2013). 
10. Grabowski, M. et al. A public database of macromolecular diffraction experiments. Acta Cryst D 72, 1181–
1193 (2016). 
11. Joosten, R. P., Long, F., Murshudov, G. N. & Perrakis, A. The PDB_REDO server for macromolecular structure 
model optimization. IUCrJ 1, 213–220 (2014). 
12. Croll, T. I., Williams, C. J., Chen, V. B., Richardson, D. C. & Richardson, J. S. Improving SARS-CoV-2 structures: 
Peer review by early coordinate release. Biophysical Journal 120, 1085–1096 (2021). 
13. Iudin, A., Korir, P. K., Salavert-Torres, J., Kleywegt, G. J. & Patwardhan, A. EMPIAR: a public archive for raw 
electron microscopy image data. Nat Methods 13, 387–388 (2016). 
 
 
14. Lawson, C. L. et al. EMDataBank.org: unified data resource for CryoEM. Nucleic Acids Res 39, D456–D464 
(2011). 
15. Joseph, A. P. et al. Refinement of atomic models in high resolution EM reconstructions using Flex-EM and 
local assessment. Methods 100, 42–49 (2016). 
16. Burnley, T., Palmer, C. M. & Winn, M. Recent developments in the CCP-EM software suite. Acta Cryst D 73, 
469–477 (2017). 
17. Mostosi, P., Schindelin, H., Kollmannsberger, P. & Thorn, A. Haruspex: A Neural Network for the Automatic 
Identification of Oligonucleotides and Protein Secondary Structure in Cryo-Electron Microscopy Maps. 
Angewandte Chemie International Edition (2020) doi:10.1002/anie.202000421. 
18. Williams, C. J. et al. MolProbity: More and better reference data for improved all-atom structure validation. 
Protein Science : A Publication of the Protein Society 27, 293 (2018). 
19. Agirre, J. et al. Privateer: software for the conformational validation of carbohydrate structures. Nat Struct 
Mol Biol 22, 833–834 (2015). 
20. Emsley, P. & Crispin, M. Structural analysis of glycoproteins: building N-linked glycans with Coot. Acta Cryst D 
74, 256–263 (2018). 
21. Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 
(2020). 
22. Kabsch, W. XDS. Acta Cryst D 66, 125–132 (2010). 
23. Yin, W. et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by 
remdesivir. Science 368, 1499–1504 (2020). 
24. Zhang, L. et al. 1′-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and 
proofreading during SARS-CoV-2 viral RNA replication. Phys. Chem. Chem. Phys. 23, 5852–5863 (2021). 
 
